DXCM - Company ID 0001093557
The table below shows DEXCOM INC's income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $4.66B | $4.03B | $3.62B | $2.91B | $2.45B | $1.93B |
| Cost of revenue | $1.86B | $1.59B | $1.33B | $1.03B | $768.00M | $646.60M |
| Gross profit | $2.80B | $2.44B | $2.29B | $1.88B | $1.68B | $1.28B |
| R&D | $599.10M | $552.40M | $505.80M | $484.20M | $517.10M | $359.90M |
DEXCOM INC reported annual revenue of $4.66B for fiscal year 2025. That is up 15.6% from $4.03B in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $573.30M (FY 2016) to $4.66B. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $1.29B |
| $1.29B |
| $1.19B |
| $1.01B |
| $810.50M |
| $618.20M |
| Operating income | $911.80M | $600.00M | $597.70M | $391.20M | $265.80M | $299.50M |
| Income tax | $252.10M | $132.80M | $168.90M | $49.60M | $39.90M | -$251.80M |
| Net income | $836.30M | $576.20M | $541.50M | $341.20M | $216.90M | $549.70M |
| EPS (diluted) | $2.09 | $1.42 | $1.30 | $0.82 | $0.53 | $1.33 |